# Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy

> **NCT01920984** · NA · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 100 (actual)

## Conditions studied

- Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** intravitreal injection of 1.25 mg of bevacizumab

## Key facts

- **NCT ID:** NCT01920984
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2013-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01920984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01920984, "Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01920984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*